22 Firstfield Road, Suite 110
About MaxCyte, Inc.
We provide our patented, high-performance cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology. With our robust delivery platform, our team of scientific experts helps our partners unlock the potential of their products and solve development and commercialization challenges.
This platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides unparalleled consistency and minimal cell disturbance – facilitating rapid, large-scale, clinical- and commercial-grade cell-engineering in a non-viral system and with low-toxicity concerns. Our cell-engineering platform is FDA-cleared, providing our customers and partners with an established regulatory path to commercialize cell-based medicines.
We are also developing novel CARMA cellular therapies for our own pipeline with our first drug candidate in a Phase I clinical trial. CARMA is MaxCyte’s novel proprietary technology for development of human mRNA-based cellular therapies to treat a broad range of diseases.
Stock Exchange: Alternative Investment Market
Stock Symbol: MXCT
At MaxCyte, we take a collaborative partnering approach with our clients with the goal of rapidly driving our partners’ development efforts forward through to commercial use, more cost-effectively and with lowered risk. We have developed and commercialized MaxCyte Scalable Transfection Systems for high-performance delivery of biomolecules using Flow Electroporation ® Technology, a proprietary cell-engineering technology designed to meet the stringent demands of clinical use – namely, the ability to safely and reproducibly modify primary human cells with high efficiency, low cytotoxicity, and at the scale required to treat patients.
142 articles with MaxCyte, Inc.
MaxCyte, Inc. Release: Company, NIH NIAID Study Published In Science Translational Medicine Demonstrates CRISPR-Cas9 Repair Of X-Linked Chronic Granulomatous Disease (CGD) Gene
MaxCyte, Inc. Announces Strategic Immuno-Oncology Collaboration To Advance New Generation Of CAR-Based Cell Therapies
MaxCyte, Inc. Announces A CRADA With US Army Medical Research Institute Of Infectious Diseases For An Exploratory Research Collaboration On Rapid Response Medical Countermeasures
MaxCyte, Inc. To Present Gene Editing Results At The American Society Of Gene And Cell Therapy Annual Meeting
MaxCyte, Inc. To Present Data On Expression And Functionality Of Bispecific Antibodies Produced Via Transient Transfection
MaxCyte, Inc. Appoints Spinco Biotech Pvt Ltd. As Distributor In India For The MaxCyte STX And MaxCyte VLX
MaxCyte, Inc.To Present Novel Approach To Car-T For Treatment Of Solid Tumors At Biochemical Society In London
MaxCyte, Inc. To Present New Data On Expression And Functionality Of Bispecific Antibodies Produced Via Transient Transfection
MaxCyte, Inc. And Johns Hopkins University Announce Strategic Immuno-Oncology Collaboration To Advance CAR T-Cell Therapies
MaxCyte, Inc. Release: Accelerating Product Development: From Transient Transfection To Stable Pools And Stable Clones